Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice.
Cell Rep Med
; 4(9): 101193, 2023 09 19.
Article
in En
| MEDLINE
| ID: mdl-37729871
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Insulin Resistance
/
Non-alcoholic Fatty Liver Disease
Type of study:
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Cell Rep Med
Year:
2023
Document type:
Article
Affiliation country:
Canada
Country of publication:
United States